登录
 机构网站
  1. 首页
  2. 情报产品
  3. 快讯详情

《Medicalxpress，1月13日，Maternal COVID-19 infection increases risks of preterm birth, low birth weight and stillbirth》

  • 来源专题：COVID-19科研动态监测
  • 编译者： YUTING
  • 发布时间：2022-01-25

  • People who contracted COVID-19 while pregnant were more likely to have poor birth outcomes including preterm birth, small for gestational age, low birth weight, and stillbirth. The poor outcomes of preterm birth and stillbirth were observed primarily with those infected with SARS-CoV-2 during the first or second trimester, whereas increased rates of small for gestational age were driven largely by third trimester infection.

    An Institute for Systems Biology-led study examined the electronic health records of more than 18,000 people with SARS-CoV-2 tests during pregnancy. Researchers compared outcomes of unvaccinated people with a positive test during pregnancy—882 in total—to those who tested negative.

    "We found that SARS-CoV-2 infection indicated increased rates of preterm delivery and stillbirth, largely driven by first and second trimester infections," said Samantha Piekos, Ph.D., first author of the study. She added: "The single greatest predictor of gestational age at delivery is gestational age at infection, with earlier age at infection associated with earlier age at delivery."

    The study results were used by the Centers for Disease Control and Prevention to support the use of booster shots.

  • 原文来源：https://medicalxpress.com/news/2022-01-maternal-covid-infection-preterm-birth.html
74浏览量
原文链接
相关报告

  • 《Medicalxpress，1月13日，WHO recommends two new drugs to treat patients with COVID-19》
    • 来源专题：COVID-19科研动态监测
    • 编译者：YUTING
    • 发布时间：2022-01-26
    • The drug baricitinib (a type of drug known as a Janus kinase (JAK) inhibitor, also used to treat rheumatoid arthritis) is strongly recommended for patients with severe or critical COVID-19 in combination with corticosteroids, says a WHO Guideline Development Group of international experts in The BMJ today. Their strong recommendation is based on moderate certainty evidence that it improves survival and reduces the need for ventilation, with no observed increase in adverse effects. The WHO experts note that baricitinib has similar effects to other arthritis drugs called interleukin-6 (IL-6) inhibitors so, when both are available, they suggest choosing one based on cost, availability, and clinician experience. It is not recommended to use both drugs at the same time. However, the experts advise against the use of two other JAK inhibitors (ruxolitinib and tofacitinib) for patients with severe or critical COVID-19 because low certainty evidence from small trials failed to show benefit and suggests a possible increase in serious side effects with tofacitinib. In the same guideline update, WHO also makes a conditional recommendation for the use of the monoclonal antibody sotrovimab in patients with non-severe COVID-19, but only in those at highest risk of hospitalization, reflecting trivial benefits in those at lower risk. A similar recommendation has been made by WHO for another monoclonal antibody drug (casirivimab-imdevimab). The experts also note that there were insufficient data to recommend one monoclonal antibody treatment over another—and they acknowledge that their effectiveness against new variants like omicron is still uncertain. As such, they say guidelines for monoclonal antibodies will be updated when additional data become available.
    86浏览量
    原文链接

  • 《Medicalxpress，2月16日，Study suggests increased risk of mental health disorders after COVID-19 infection》
    • 来源专题：COVID-19科研动态监测
    • 编译者：YUTING
    • 发布时间：2022-03-02
    • A study published by The BMJ today finds that COVID-19 is associated with an increased risk of mental health disorders, including anxiety, depression, substance use, and sleep disorders, up to one year after initial infection. The findings suggest that tackling mental health disorders among survivors of COVID-19 should be a priority. Some studies have suggested that people with COVID-19 might be at increased risk of anxiety and depression, but they included only a small selection of mental health outcomes and tracked patients over a maximum of six months. A comprehensive assessment of the mental health manifestations in people with COVID-19 at one year has not yet been undertaken. To address this, researchers used data from the US Department of Veterans Affairs national healthcare databases to estimate the risks of mental health outcomes in people who survived at least 30 days after a positive polymerase chain reaction (PCR) test result between March 2020 and January 2021. They identified data for 153,848 individuals and matched them to two control groups without COVID-19: 5,637,840 contemporary controls and 5,859,251 historical controls who predated the pandemic. Participants were mostly white men with an average age of 63 years. The COVID-19 group was further divided into those who were or were not admitted to hospital during the acute phase of infection, and information was collected on potentially influential factors including age, race, sex, lifestyle, and medical history. The researchers then followed all three groups for one year to estimate the risks of a set of prespecified mental health outcomes, including anxiety, depression and stress disorders, substance use disorders, neurocognitive decline, and sleep disorders. Compared with the non-infected control group, people with COVID-19 showed a 60% higher risk of any mental health diagnosis or prescription at one year (equivalent to an additional 64 per 1,000 people). When the researchers examined mental health disorders separately, they found that COVID-19 was associated with an additional 24 per 1,000 people with sleep disorders at one year, 15 per 1,000 with depressive disorders, 11 per 1,000 with neurocognitive decline, and 4 per 1,000 with any (non-opioid) substance use disorders.
    117浏览量
    原文链接